Patent · US Active

Lisinopril formulations

US12128083B2 · kind B2 · utility

0Cited by
33References
19Claims
0Family size

Assignee

Inventors

Key dates

Filing dateAug 16, 2023
Grant dateOct 29, 2024
Priority date
Expiry dateAug 16, 2043

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K47/26
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.